Krystal Biotech Inc (KRYS) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

KRYS ranks #1431 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

KRYS is a top-conviction position for Redmile Group, LLC — at 15.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in KRYS belongs to FMR LLC, but the position matters far more to Redmile Group, LLC, who has 15.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its KRYS position for two straight quarters, increasing it by $583.3M to reach $1.6B today.

TD Asset Management Inc has trimmed its KRYS position for two straight quarters, cutting it by $4.9M while still holding $8.4M.

KRYS is up 1% today, and institutions have been net buyers of $3.2B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

KRYS posted net income of $241.5M over the trailing twelve months, and currently trades at a P/E of 44.6.

• Profitable — net income of $241.5M over the trailing twelve months
• Revenue grew 22.6% year over year
• Net income improved year over year, from $146.7M to $241.5M
• Generated $200.9M in positive operating cash flow
• Current ratio of 9.95x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range